Načítá se...
Biosimilars in the management of neutropenia: focus on filgrastim
Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to...
Uloženo v:
| Vydáno v: | Biologics |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762467/ https://ncbi.nlm.nih.gov/pubmed/26937170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S73580 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|